Humatin Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians prescribing paromomycin (Humatin), the pharmacokinetics and clinical role of the drug are well understood. What is often less clear is navigating the real-world access barriers patients face when trying to fill this prescription. This article is designed to help providers anticipate and address those barriers proactively — so your patients actually receive the treatment you intend them to have.

Clinical Context: Why Paromomycin Is Still Prescribed

Paromomycin (Humatin) occupies a specific niche in anti-infective therapy: it is a non-absorbed aminoglycoside that acts as a luminal amebicide and has bactericidal activity in the intestinal lumen. Its primary FDA-approved indications are:

• Intestinal amebiasis (acute and chronic): As a luminal agent, typically following a course of metronidazole or tinidazole to clear residual cysts. IDSA guidelines recommend paromomycin or iodoquinol as the luminal agent in combination therapy for symptomatic or invasive amebiasis.
• Adjunctive therapy for hepatic coma: Though less preferred than lactulose or rifaximin in current guidelines, paromomycin reduces intestinal ammonia-producing bacteria and has historical use in acute hepatic encephalopathy management.

Off-label uses include giardiasis in pregnancy (where nitroimidazoles carry greater risk), Dientamoeba fragilis infection (where a 2019 comparative study showed paromomycin superior to metronidazole in eradication rates), and cryptosporidiosis in immunocompromised patients in conjunction with azithromycin or nitazoxanide.

The Access Problem: What Your Patients Will Encounter

Despite not being on the FDA's formal shortage list, Humatin is functionally unavailable at most retail pharmacies. The key factors driving this:

• Generic discontinuation: The generic paromomycin sulfate capsule has been discontinued, leaving only brand-name Humatin from Waylis Therapeutics. This eliminates the pricing competition and broad distribution that generics provide.
• Exorbitant pricing: Retail cost ranges from approximately $3,000–$6,000 for a treatment course. Most retail pharmacies will not stock medications with this price point and this low turnover.
• Limited distribution: The drug flows through specialty pharmacy channels rather than general wholesale distribution.
• Insurance prior authorization: Most insurers require prior authorization and some require confirmation of diagnosis through lab results. The PA process can delay treatment by days to weeks.

Prior Authorization: What to Include in Your Submission

When submitting a prior authorization for Humatin, include the following to maximize approval likelihood on first submission:

• Confirmed diagnosis with laboratory evidence (stool antigen testing or PCR for E. histolytica; stool O&P results)
• Documentation that treatment is prescribed by or in consultation with a gastroenterologist or infectious disease physician (many PBM criteria require this)
• ICD-10 codes: A06.0 (acute amebic dysentery), A06.1 (chronic intestinal amebiasis), or A06.9 (amebiasis unspecified) as appropriate
• Intended dose and duration (25-35 mg/kg/day in 3 divided doses for 5-10 days for amebiasis)
• Rationale for paromomycin specifically (e.g., pregnancy where nitroimidazoles are contraindicated; luminal clearance following tissue-phase treatment)

Where to Direct Patients for Dispensing

Rather than sending patients to a retail chain and hoping for the best, direct them to resources with higher success rates:

• Specialty infectious disease pharmacies — These typically have relationships with Waylis Therapeutics and can source Humatin reliably.
• Your institution's outpatient pharmacy — If you practice at a hospital or academic medical center, your outpatient pharmacy is likely the most reliable source.
• Waylis TotalCare program — The manufacturer (844-200-7910) can connect patients to dispensing pharmacies and provide financial assistance for eligible patients.
• medfinder for providers — medfinder.com/providers allows you to search pharmacies on behalf of patients, identifying which locations can fill the prescription before your patient even leaves your office.

When to Consider Alternatives

If Humatin is genuinely inaccessible or unaffordable for your patient, clinical alternatives to consider based on indication:

• Luminal amebicide substitute: Iodoquinol 650 mg TID x 20 days (though note this also has limited availability in the U.S.)
• Hepatic encephalopathy: Lactulose first-line; rifaximin (Xifaxan) as add-on. Both preferred over paromomycin in current guidelines.
• Giardiasis in pregnancy: Consider delaying treatment to second trimester when metronidazole has better safety data, or pursue specialty consultation.
• D. fragilis: Metronidazole or tetracycline, though evidence suggests paromomycin may have superior eradication. Consider infectious disease consultation.

Documentation and Advocacy

When patients are unable to access prescribed antiparasitic medications, document this in the medical record. Note the prescribing intent, access barriers encountered, and any alternative treatment path taken. This documentation supports appeals if insurance is denied and contributes to the broader data picture that researchers and policymakers need to advocate for improved access to niche antiparasitic drugs.